Research on cancer as a disease, from cause to care. Covers tumor biology, small-cell lung cancer, cancer-linked stroke risk, and cancer center research.
The 250,000-square-foot facility provides greater availability to high-quality integrated care, addressing the region's increasing demand for innovative diagnostic and treatment services. The pavilion brings together a broad range of nationally ranked clinical programs, including cancer clinics, neurology, and surgery.
Researchers at UC San Diego School of Medicine have developed a novel approach to enhance the effectiveness of immunotherapy treatments for head and neck squamous cell carcinomas (HNSCC). Delivering radiation therapy that preserves tumor-draining lymph nodes followed by immunotherapy resulted in a complete and durable tumor response in...
A single bout of exercise increases myokine levels, reducing cancer growth by 20-30%. Regular exercise helps reduce inflammation and improve body composition, leading to a lower risk of recurrence and mortality.
A study published in Cancer Biology & Medicine found that combining mitochondrial transplantation with cisplatin enhances immune cell infiltration, reverses tumor metabolism, and improves the effectiveness of chemotherapy. This innovative approach shows potential to reshape how lung tumors are treated.
Three in five liver cancer cases can be prevented by reducing viral hepatitis, alcohol consumption, and metabolic dysfunction-associated steatotic liver disease. The Lancet Commission estimates that if countries can reduce liver cancer incidence by 2-5% annually by 2050, it could prevent 9-17 million new cases and save 8-15 million lives.
A new silicone patch with star-shaped microneedles, called the ExoPatch, distinguishes melanoma from healthy skin in mice, capturing cancer biomarkers from exosomes. The test shows promise for early detection of the most aggressive form of skin cancer without a biopsy or blood draw.
Researchers have discovered a promising new approach to suppress the growth of aggressive cancers by targeting minor splicing, a specialized molecular process. By blocking minor splicing, cancer cells accumulate DNA damage and trigger cell death, while healthy cells remain largely unaffected.
Scientists have found that nucleosomes act as gatekeepers for p53's molecular partners, controlling its access to the genetic code. This discovery reveals a new layer of regulation over p53's activity and opens possibilities for developing cancer therapies that restore or control p53 function.
A team of scientists from the University of Konstanz has identified the PPM1F enzyme as essential for cell migration in both embryonic development and tumor cell invasion. The study found that increased levels of PPM1F enhance the invasive potential of cancer cells, while its absence impairs cell adhesion and migration.
Colorectal cancer claims more lives in Black communities than any other racial group, with incidence and mortality rates about 20% and 30% higher respectively. A new review by UCLA researchers highlights the need for equal access to screening, diagnosis, and treatment to eliminate these disparities.
A new study identified seven immune-related genes downregulated in hepatocellular carcinoma and intrahepatic cholangiocarcinoma, which are associated with immune surveillance and complement pathways. The findings also revealed macrophage migration inhibitory factor signaling as a critical communication channel in ICC.
Researchers at Fralin Biomedical Research Institute have identified a potential target for experimental drugs that block PRMT5, a naturally occurring enzyme some tumors rely on for survival. The study found a new drug combination that works against certain hard-to-treat cancers.
Researchers at Sanford Burnham Prebys found that blocking macropinocytosis reshapes the tumor microenvironment, allowing more access to immune cells. This change made immunotherapy and chemotherapy more effective in treating PDAC tumors in mice.
A new case report describes the use of extracorporeal blood filtration to treat stage IV poorly differentiated pancreatic adenocarcinoma. The patient experienced clinical improvement, reduced pain, and no signs of new tumor growth over 12 months of follow-up.
The Josep Carreras Leukaemia Research Institute is launching a joint research programme on childhood leukaemia, aiming to develop common strategies and improve treatments for the disease. Paediatric leukaemia remains a significant challenge due to its low incidence and high mortality rate.
Diana Hargreaves will receive $1 million to advance her project on improving immunotherapy in patients with pancreatic cancer. Her previous work identified better drug targets for cancers with SWI/SNF mutations, leading to breakthroughs in treating difficult-to-treat cancers.
Researchers found that oxidative stress actually suppressed cancer development in rats with BRCA2 gene mutations, contrary to prior expectations. This discovery suggests that avoiding radiation exposure may not be the best method for people with BRCA2 pathological variants.
Researchers at the University of Illinois found that benign and cancerous breast calcifications have unique structures and formation processes. The study provides a new classification scheme and opens the possibility of treating benign calcifications using certain drugs.
A new study published in The Lancet Public Health found that walking 7000 steps a day offers similar health benefits as walking 10,000 steps. The research analyzed data from 57 studies and found significant improvements in eight major health outcomes, including reduced risk of cardiovascular disease, dementia, and depressive symptoms.
A team from The Hebrew University of Jerusalem has developed innovative druglike molecules capable of degrading HuR, a key RNA-binding protein that stabilizes oncogenes and fuels cancer progression. These molecular degraders improve anticancer properties by up to 3-4 orders of magnitude compared to traditional HuR-binding molecules.
A study published in Nature found that autoantibodies can tilt the odds dramatically toward shrinking tumors and enhance the effectiveness of immunotherapy. Certain autoantibodies linked to better clinical outcomes could reveal cancer's weak spots and point to new targets for treatment.
Researchers discovered a compound, EPS3.9, produced by deep-sea bacteria that triggers pyroptosis to inhibit tumor growth and exhibit potent anti-cancer effects. The study highlights the importance of exploring marine microbial resources for developing new drugs.
The Weill Cancer Hub West will harness expertise from two world-class institutions to accelerate new discoveries and develop innovative treatments. The initiative aims to drive early detection, diagnoses, and effective treatments through data science and human cell research.
A new breath test has been developed to detect blood cancers, showing promise for early diagnosis and treatment monitoring. The test uses exhaled breath analysis to identify molecules produced by cancer cells, potentially providing a quick and affordable diagnostic tool for areas with limited access to specialist equipment.
A study published in Frontiers in Veterinary Science found that Elenagen significantly reduced chronic osteoarthritis pain scores in dogs, achieving a 90% success rate. The therapy works by reprogramming aged or dysfunctional mesenchymal stem cells, which then produce anti-inflammatory signals and restore their regenerative capacity.
Researchers discovered that statins selectively modulate key components of the Wnt/β-catenin signaling pathway, leading to lower levels of tumor-promoting proteins and cancer-suppressing cellular behaviors. Statins downregulate SATB1 while increasing SATB2, making cancer cells less able to grow and spread.
CORNETO enables researchers to extract molecular networks by combining experimental data with prior biological knowledge, helping to better understand cell health and disease mechanisms. The tool identifies shared pathways and patient-specific differences, a step toward personalised treatment strategies.
City of Hope research demonstrates a new drug combination that slows advanced prostate cancer growth without improving overall survival. A novel AI conversation tool helps scientists uncover gene-disease connections without programming expertise.
Researchers have identified CDX1 and CDX2 as key molecules that counteract β-catenin and suppress stemness in colon cancer. Deletion or overexpression of these proteins increased tumor aggressiveness and expression of cancer stemness-related genes, suggesting a potential therapeutic target.
Researchers at MURR have optimized Terbium-161 for radiopharmaceutical use, enabling targeted destruction of cancer cells with high-energy electrons. The breakthrough could add extra therapeutic effectiveness to existing treatments without requiring new drug development.
By reprogramming chromatin to prevent cancer cells from adapting to evade treatment, researchers have doubled chemotherapy effectiveness in animal experiments. This approach restores cellular memory, making existing drugs more effective against cancer.
Researchers at UC San Diego School of Medicine have discovered a link between stress and inflammation and pancreatic ductal adenocarcinoma (PDAC), a type of aggressive and lethal cancer. The findings could lead to the detection of PDAC before it becomes life-threatening, enabling early screening tools for precision medicine.
An international research team has identified three key genes involved in controlling the invasion routes of glioblastoma. The study found that targeting these genes may lead to a potential new treatment strategy for the aggressive brain tumor.
Researchers at Helmholtz Munich discovered that liver metabolism is reprogrammed in cachexia, with a specific gene called REV-ERBα being almost completely shut down. This 'internal clock' regulates liver-derived signaling molecules that drive disease progression and promote physical wasting.
Scientists developed a material that can stick to tumors, pumping out chemotherapy drugs for days, minimizing impact on healthy tissue. Early results show great promise for reducing clinical treatments and improving patient outcomes.
Researchers analyzed US cancer registration systems and found disparities in racial minorities' representation, despite revisions to the established standards. The study revealed significantly lower rates for American Indian or Alaskan Native populations under the 1997 standards compared to the previous 1977 standards.
Patients with common cancers face significant out-of-pocket costs after diagnosis, with the most advanced cases having the highest expenses. Further research is needed to understand the clinical and financial implications of these costs.
Researchers at NTU Singapore and Oxford University have discovered a mechanism by which cells identify and repair highly toxic DNA damage, known as DPCs, that cause cancer, neurodegeneration, and premature ageing. The study reveals how SPRTN, a key repair enzyme, selectively targets DPC lesions, increasing its activity 67-fold.
Researchers have identified a key gene crucial for vitamin D uptake and metabolism, offering new avenues for precision medicine in cancer therapy and potential benefits for autoimmune diseases. Inhibiting this gene may selectively kill cancer cells while leaving healthy tissues unharmed.
Researchers highlight microRNAs as crucial biomarkers for diagnosing and monitoring soft tissue sarcomas, with potential for precision medicine. MicroRNAs could help distinguish between tumor types and guide treatment decisions.
Researchers at Hiroshima University have found that fermenting stevia leaf extract with bacteria kills off pancreatic cancer cells without harming healthy kidney cells. The study identified chlorogenic acid methyl ester as the active anti-cancer compound, which exhibits stronger toxicity to cancer cells than chlorogenic acid alone.
New research from Sylvester Comprehensive Cancer Center shows that partial match transplants can achieve good outcomes with cyclophosphamide treatment. Additionally, lifestyle medicine is playing a pivotal role in improving patient outcomes for cancer survivors.
A recent study identified 37 human-specific genes linked to brain development and cognitive abilities, which are hijacked by cancer to drive tumor growth. The researchers discovered nearly half of these genes become aberrantly activated in cancerous tissues, promoting tumor cell proliferation.
The study reveals diverse microbial profiles within different tumor types, with notable diversity in species composition and spatial localization. Functional effects of intratumoral microbiota on the tumor microenvironment range from immunostimulatory to protumor.
Researchers have discovered an experimental mRNA vaccine that can boost tumor-fighting effects of immunotherapy, sparking a new approach to battling many types of treatment-resistant tumors. The study found that pairing the test vaccine with common anticancer drugs triggered a strong antitumor response.
A recent study published in JAMA Network Open found that glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment was associated with reduced all-cause mortality among older patients with cancer and type 2 diabetes. The survival benefit persisted across various subgroups, including age, sex, and cancer type.
Researchers Sontheimer and Monje have made groundbreaking discoveries in brain tumor growth, revealing how nerve cells promote the development of aggressive gliomas. Their work has laid the foundation for new treatments and clinical trials, offering hope for innovative therapies.
A new study published in JAMA Oncology found that vaccinated cancer patients are at lower risk for hospitalization and severe illness from COVID-19. The research analyzed data on over 161,000 cancer patients treated during 2022 and 2023, showing a significant reduction in hospitalizations by 29%.
ADLM 2025 will tackle urgent topics like clinical AI integration and fake medical news, as well as leveraging genomics for personalized healthcare. The meeting also explores the health threat of plastics and microbiome medicine to combat diseases.
A retrospective cohort study found that COVID-19 booster vaccinations significantly protected against severe COVID-19, but uptake was low. Interventions are needed to increase COVID-19 vaccine uptake among high-risk populations with cancer.
A study found that children who lived near Coldwater Creek, a Missouri River tributary polluted by nuclear waste, had a higher risk of developing cancer. The researchers estimated that those living less than one kilometer away from the creek had a 44% higher risk of cancer compared to those living more than 20 kilometers away.
Researchers developed a new method to generate CAR-T cells in laboratory mice with mRNA-based vaccines, which proved effective and safe. The approach eradicated tumors in 75% of mice with B cell lymphoma after several doses.
Researchers identified key factors behind a successful immunotherapy response in a young patient with rhabdoid tumour. The study highlights the potential of sequencing technologies to track immune cell profiles and develops personalized cell therapies.
Researchers at MD Anderson identified specific co-mutations in KRAS-mutant non-small cell lung cancer (NSCLC) that improve treatment response to ATR inhibitors. Additionally, chemotherapy was found to drive changes to the genome and clonal architecture of blood stem cells, increasing the risk of secondary malignancies.
A team led by University of Houston engineer Tianfu Wu aims to find better biomarkers for ovarian cancer using autoantibodies and machine learning. By detecting ovarian cancer earlier, mortality rates could be reduced by 10-30%.
Researchers explore the design of microrobots for targeted cancer therapy, including tumor cell eradication, improved penetration, and immune system modulation. The review also discusses advanced delivery strategies and imaging technologies to enhance treatment efficiency and precision.
Chemotherapy-induced pyroptosis in bladder cancer can actually make the disease more resistant to treatment by fueling cancer stem cells. Blocking this inflammatory process with belnacasan may overcome chemoresistance in preclinical models.
This special issue focuses on cutting-edge advancements in polypharmacology for cancer therapy, addressing mechanisms of drug resistance and rational design of drug combinations. It also covers computational and AI-driven methodologies for discovering novel polypharmacological agents.
Researchers used AI model ChatGPT-4 to extract clinical variables from MRI and CT scans of nearly 1,000 adults with pancreatic cysts. The accuracy rate ranged from 97% for solid components to 99% for calcific lesions, comparable to human performance.
A new study found that exercise can improve the quality of life and symptom management for CLL patients, but personalized guidance is needed. Patients prefer virtual classes, expert advice from cancer care specialists, and tailored programs addressing their unique challenges.